If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Vitrification (from Latin vitrum 'glass', via French vitrifier) is the full or partial transformation of a substance into glass. In the production of ceramics, vitrification is responsible for their impermeability to water. The most common applications are in the making of pottery, glass, and some types of food, but there are many others, such as the vitrification of an antifreeze-like liquid in cryopreservation. Vitrification is also used in the disposal and long-term storage of radioactive waste, in which the waste is immobilized within a hardened glass material considered more stable for containment. It has also been proposed, though disputed, that the extreme heat of the eruption of Mount Vesuvius in 79 AD vitrified the brain of at least one victim.
=== OECD === In October 2021, Castillo sent a letter to the secretary-general of the Organisation for Economic Co-operation and Development (OECD), Mathias Cormann, to ratify Peru's willingness to join the organization. In January 2022, Castillo signed the invitation letter to begin Peru's accession process to the OECD.
Syringomycin E is a member of a class of lipodepsinonapeptide molecules that are secreted by the plant pathogen Pseudomonas syringae. Lipodepsinonapeptides comprise a closed ring of nine nonribosomally synthesized amino acids bonded to a fatty acid hydrocarbon tail. A commonly encountered pathovar (pv) of P. syringae is P. syringae pv syringae, which secretes a number of closely related forms of the molecule. Syringomycins are virulence determinants, which means that their secretion is required for the manifestation of disease symptoms on a number of stone fruit crop plants. Syringomycins have two widely recognized mechanisms of action. They can function as detergents which are powerful enough to dissolve plant membranes at high concentrations. It is not clear whether concentrations high enough to dissolve membranes are ever reached in planta. In addition to being surfactants, aggregates of syringomycins can insert into plant cell membranes and form small pores. These pores allow the leakage of ions from the plant cell cytoplasm. Affected plant cells are unable to maintain their required levels of electrolyte and ultimately cell death and lysis occurs. It is believed that P. syringae benefits from the release of nutrients that occurs as a consequence of cellular lysis. The biosynthesis of this class of molecules has been elucidated.
== History == Clomipramine was developed by Geigy as a chlorinated derivative of imipramine. It was first referenced in the literature in 1961 and was patented in 1963. The drug was first approved for medical use in Europe in the treatment of depression in 1970, and was the last of the major TCAs to be marketed. In fact, clomipramine was initially considered to be a "me-too drug" by the FDA, and in relation to this, was declined licensing for depression in the United States. As such, to this day, clomipramine remains the only TCA that is available in the United States that is not approved for the treatment of depression, in spite of the fact that it is a highly effective antidepressant. Clomipramine was eventually approved in the United States for the treatment of OCD in 1989 and became available in 1990. It was the first drug to be investigated and found effective in the treatment of OCD. The benefits in OCD were first reported by Juan José López-Ibor in 1967, and the first double-blind, placebo-controlled clinical trial of clomipramine for OCD was conducted in 1976, with more rigorous clinical studies that solidified its effectiveness conducted in the 1980s. It remained the "gold standard" for the treatment of OCD for many years until the introduction of the SSRIs, which have since largely superseded it due to greatly improved tolerability and safety (although notably not effectiveness).
Selegiline has been limitedly studied in large animals like horses and its dosage in these animals has not been established. In preliminary research, a dose of selegiline of 30 mg orally or intravenously in horses had no observable effects on behavior or locomotor activity. The doses of selegiline used in animals are described as extremely high relative to those used in humans (which are ~0.1 mg/kg body weight).
Sources: en.wikipedia.org
In August 2022, the Inflation Reduction Act passed, requiring companies to cap the price of insulin at US$35 per month for Medicare. On November 10, a Twitter account impersonating the pharmaceutical company Eli Lilly and Company—one of the three largest manufacturers of insulin—posted a tweet stating that insulin would be made free. According to The Washington Post, Twitter failed to respond to the company for several hours. The incident resulted in Eli Lilly pulling advertisements from Twitter. United States senator Bernie Sanders used the tweet to highlight the price of insulin as other users began creating satirical accounts jovially apologizing for making insulin free, with one such account writing, "Humalog is now $400. We can do this whenever we want and there's nothing you can do about it". The identity of the user who posted the tweet remained unknown until November 22, when Sean Morrow, a 34-year-old writer for the media organization More Perfect Union, admitted to operating the account and writing the tweet. In a video, Morrow stated that he used the account of the Mothman running for the United States Senate for West Virginia, and put that the account was a parody in its biography. Morrow took the video to detail the history of insulin manufacturing and the monopolization of the insulin industry. Eli Lilly further lowered the price of insulin in March 2023.
==== Fungal origin ==== Sometimes fungal infections occur on the gums. Candida species such as C. albicans, C. glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. guillermondiiare the most common fungi capable of causing gingival lesions. Linear gingival erythema is classified as a candida-associated lesion, that is to say Candida species are involved, and in some cases the lesion responds to antifungal therapy, but it is thought that other factors exist, such as oral hygiene and human herpesviruses. Linear gingival erythema presents as a localized or generalized, linear band of erythematous (red) gingivitis. It was first observed in HIV infected individuals and termed "HIV-gingivitis", but the condition is not confined to this group. This condition can develop into necrotizing ulcerative periodontitis. Histoplasma capsulatum is the causative organism in histoplasmosis, which may occasionally involve the gums.
The current treatment of choice is the intravenous administration of dantrolene, the only known antidote, discontinuation of triggering agents, and supportive therapy directed at correcting hyperthermia, acidosis, and organ dysfunction. Treatment must be instituted rapidly on clinical suspicion of the onset of malignant hyperthermia.
– details how the Philippine Constabulary, aided by the Scout Rangers, defeated the Huk insurgency in Central Luzon. Weir, Fraser (1998). "American Colony and Philippine Commonwealth 1901–1941". A Centennial History of Philippine Independence, 1898–1998. Archived from the original on July 24, 2020. Retrieved July 24, 2020. "IV. The Rebirth of the Army". (Title unknown).
Sources: en.wikipedia.org
These errors or mutations lead to the expression of a mutant huntingtin protein, which contains repetitive glutamine residues that are encoded by expanding CAG trinucleotide repeats in the gene. Huntington's disease is characterized by neuronal loss and gliosis. Symptoms of the disease include: movement disorder, cognitive decline, and behavioral disorder.
Layne Thomas Staley (; born Layne Rutherford Staley; August 22, 1967 – April 5, 2002) was an American singer-songwriter. He was the original lead vocalist of Alice in Chains, which rose to international fame in the early 1990s as part of Seattle's grunge movement. He was known for his distinctive vocal style as well as his harmonizing with bandmate Jerry Cantrell. Before his success with Alice in Chains, Staley was also a member of the glam metal bands Sleze and Alice N' Chains. He was also a part of the supergroups Mad Season and Class of '99. "Man in the Box", the second single from Alice in Chains' debut album, Facelift (1990), garnered Staley critical recognition for his vocal style. Alice in Chains' EP Jar of Flies (1994), debuted at number one on the Billboard 200, making it Alice in Chains' first record—and the first-ever EP—to top the chart. However, Staley's deteriorating condition due to heroin abuse led him to enter a rehabilitation clinic. He began to work on a side project with several Seattle musicians, Mike McCready of Pearl Jam, Barrett Martin of Screaming Trees, and John Baker Saunders of the Walkabouts, which came to be Mad Season, while Alice in Chains went into hiatus. During Alice in Chains' hiatus, reports of Staley's drug addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. On April 10, 1996, the band returned with a performance on MTV Unplugged in New York; it was Alice in Chains' first concert in two-and-a-half years.
The USSR also included most of the world's largest lakes; the Caspian Sea (shared with Iran), and Lake Baikal, the world's largest (by volume) and deepest freshwater lake that is also an internal body of water in Russia.
== Early life and education == Kimmel was born to a Jewish family in the Bronx on April 9, 1916, one of four sons of Henry and Emma Kimmel. His father, Henry Kimmel, managed a family-run lighting fixture store. After wiring many new buildings, he started buying property and built many multi-family residential buildings in New York City. Kimmel attended Syracuse University but left to serve in the Army during World War II in the Pacific theater. Upon returning to the US, he worked with his father at the lighting store, and then for the construction company Henry Kimmel and Sons, where he learned about the homebuilding industry. Based with this knowledge, he started his own company on Long Island which built garden apartments.
an aromatic aldehyde + NADH + H+ The two substrates of this enzyme are an aromatic alcohol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are the corresponding aromatic aldehyde, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is aryl-alcohol:NAD+ oxidoreductase. Other names in common use include p-hydroxybenzyl alcohol dehydrogenase, benzyl alcohol dehydrogenase, and coniferyl alcohol dehydrogenase. This enzyme participates in 5 metabolic pathways: tyrosine metabolism, phenylalanine metabolism, biphenyl degradation, toluene and xylene degradation, and caprolactam degradation.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.